Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Ipsen Upbeat Despite Palovarotene Pain

Healthy Sales Rise In 2019

Feb 14 2020

• By Kevin Grogan

Balancing — On balance, 2019 was a decent one for Ipsen • Source: Shutterstock

Related Content

Ipsen CBO: We Are Seeking Fresh Rare Disease Buys

Nov 25 2019

Ipsen Commercial Chief: Buying Clementia Will Bolster Rare Disease Franchise

Feb 25 2019

Ipsen’s Palovarotene Hit By FDA Clinical Hold

Dec 09 2019

Blow To Ipsen As FerGene Nabs CEO Meek

Dec 18 2019

Related Companies

Ipsen SA

Clementia Pharmaceuticals, Inc.

FerGene

Blueprint Medicines Corporation

Novartis AG

Additional Topics

Sales & Earnings Rare Diseases Commercial Clinical Trials Cancer BioPharmaceutical

More from Earnings

More from Business

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window